Rallybio Corp (RLYB)

Dec 19, 2024

Rallybio stock plunges to 52-week low, touches $0.94 - Investing.com

Dec 19, 2024

Dec 15, 2024

Rallybio's SWOT analysis: rare disease biotech stock faces pivotal phase - Investing.com

Dec 15, 2024

Dec 15, 2024

Rallybio's SWOT analysis: rare disease biotech stock faces pivotal phase By Investing.com - Investing.com UK

Dec 15, 2024

Dec 12, 2024

US Penny Stocks To Consider In December 2024 - Simply Wall St

Dec 12, 2024

Dec 10, 2024

RLYBRallybio Corporation Latest Stock News & Market Updates - StockTitan

Dec 10, 2024

Dec 10, 2024

Rallybio Corporation Announces Promising RLYB212 and RLYB332 Preclinical Data at 66th American Society of Hematology Annual Meeting - Marketscreener.com

Dec 10, 2024

Dec 10, 2024

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66 - Business Wire

Dec 10, 2024

Dec 10, 2024

Rallybio's ASH Data Shows Breakthrough Potential in Blood Disorder Treatments, Strong Preclinical Results - StockTitan

Dec 10, 2024

Dec 06, 2024

Rallybio price target lowered to $7 from $8 at JMP Securities - Yahoo Finance

Dec 06, 2024

Dec 05, 2024

Rallybio (NASDAQ:RLYB) Earns Buy Rating from HC Wainwright - Defense World

Dec 05, 2024

Dec 04, 2024

Rallybio shares retains Buy rating on treatment potential By Investing.com - Investing.com Australia

Dec 04, 2024

Dec 03, 2024

Rallybio shares retains Buy rating on treatment potential - Investing.com

Dec 03, 2024

Dec 02, 2024

Rallybio : RLYB116 Clinical Program Update – Harnessing the Power of C5 Inhibition - Marketscreener.com

Dec 02, 2024

Dec 02, 2024

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025 - Business Wire

Dec 02, 2024

Nov 28, 2024

Rallybio advances Phase 2 trial for rare pregnancy condition By Investing.com - Investing.com Nigeria

Nov 28, 2024

Nov 27, 2024

Rallybio Flat On Release Of New Findings - MENAFN.COM

Nov 27, 2024

Nov 27, 2024

Rallybio Flat on Release of New Findings - Baystreet.ca

Nov 27, 2024

Nov 27, 2024

Rallybio advances Phase 2 trial for rare pregnancy condition - Investing.com

Nov 27, 2024

Nov 27, 2024

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women - Business Wire

Nov 27, 2024

Nov 27, 2024

U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.01% - MSN

Nov 27, 2024

Nov 26, 2024

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference - Marketscreener.com

Nov 26, 2024

Nov 25, 2024

Rallybio's SWOT analysis: rare disease biotech stock advances FNAIT treatment - Investing.com

Nov 25, 2024

Nov 25, 2024

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor - Business Wire

Nov 25, 2024

Nov 25, 2024

Rallybio to Host Key Webcast on RLYB116 C5 Inhibitor Development Updates - StockTitan

Nov 25, 2024

Nov 23, 2024

Rallybio commences Phase II trial of RLYB212 for FNAIT in pregnant women - Clinical Trials Arena

Nov 23, 2024

Nov 21, 2024

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212 - Business Wire

Nov 21, 2024

Nov 21, 2024

Rallybio Launches Phase 2 Trial for Groundbreaking Pregnancy Treatment RLYB212 - StockTitan

Nov 21, 2024

Nov 15, 2024

Rallybio stock hits 52-week low at $0.96 amid market challenges - Investing.com India

Nov 15, 2024

Nov 13, 2024

FMR LLC Acquires Shares in Rallybio Corp - GuruFocus.com

Nov 13, 2024

Nov 12, 2024

HC Wainwright Issues Pessimistic Forecast for Rallybio (NASDAQ:RLYB) Stock Price - Defense World

Nov 12, 2024

Nov 08, 2024

Staff cuts help New Haven-based biotech Rallybio reduce 3Q loss - Hartford Business Journal

Nov 08, 2024

Nov 08, 2024

Rallybio Co. (NASDAQ:RLYB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Nov 08, 2024

Nov 07, 2024

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates - BioSpace

Nov 07, 2024

Nov 05, 2024

Two former Alexion leaders fight through a tough market to maintain a rare disease biotech - PharmaVoice

Nov 05, 2024

Oct 30, 2024

Rallybio stock plunges to 52-week low at $0.99 amid market challenges - Investing.com Canada

Oct 30, 2024

Oct 30, 2024

Rallybio advances novel FNAIT prevention trial By Investing.com - Investing.com Canada

Oct 30, 2024

Oct 29, 2024

Rallybio advances novel FNAIT prevention trial - Investing.com India

Oct 29, 2024

Oct 29, 2024

Rallybio stock plunges to 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa

Oct 29, 2024

Oct 29, 2024

Rallybio’s trial applications of RLYB212 in pregnant women with FNAIT approved - TipRanks

Oct 29, 2024

Oct 29, 2024

Rallybio to Begin First Clinical Trial for Prevention of Rare Pregnancy Blood Disorder - Femtech Insider

Oct 29, 2024

Oct 29, 2024

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT - Business Wire

Oct 29, 2024